- Home
- ACIU vs GHI Comparison
ACIU vs GHI Comparison
Compare ACIU & GHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACIU | GHI |
|---|---|---|
| Founded | 2003 | 1998 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 213.3M | 161.5M |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | ACIU | GHI |
|---|---|---|
| Price | $3.09 | $7.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $10.00 | ★ $13.00 |
| AVG Volume (30 Days) | ★ 1.4M | 170.5K |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | ★ 21.05% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.17 |
| Revenue | $5,482,957.00 | ★ $26,247,399.00 |
| Revenue This Year | N/A | $201.02 |
| Revenue Next Year | $738.95 | $2.87 |
| P/E Ratio | ★ N/A | $41.67 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.43 | $6.01 |
| 52 Week High | $4.00 | $13.29 |
Technical Indicators
Market Signals| Indicator | ACIU | GHI |
|---|---|---|
| Relative Strength Index (RSI) | 53.05 | 50.77 |
| Support Level | $2.87 | $6.75 |
| Resistance Level | $3.21 | $7.50 |
| Average True Range (ATR) | 0.29 | 0.31 |
| MACD | 0.03 | 0.13 |
| Stochastic Oscillator | 46.83 | 61.01 |
Price Performance
Historical ComparisonAbout ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About GHI Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests
Greystone Housing Impact Investors LP engaged in acquiring a portfolio of mortgage revenue bonds (MRBs) that are issued by state and local housing authorities to provide construction and/or permanent financing for affordable multifamily housing, seniors housing, and commercial properties. It has four reportable segments, namely Affordable Multifamily MRB Investments, Seniors and Skilled Nursing MRB Investments, MF Properties, and Market-Rate Joint Venture Investments. It generates the majority of its revenue from the Affordable Multifamily MRB Investments segment.